Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bril

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
The Journal of Clinical Endocrinology and Metabolism|February 11, 2026
Severity of MASH Activity by Iron-Corrected MRI Predicts Insulin Resistance and Cardiometabolic Risk in Type 2 DiabetesAndrea Ortiz Rocha, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Diabetes, Obesity & Metabolism|April 29, 2026
High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology ClinicsSrilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, et al.
Obesity (Silver Spring, Md.)|September 24, 2024
Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screenAnu Sharma, Eddison Godina Leiva, Srilaxmi Kalavalapalli, et al.
Journal of Hepatology|January 17, 2025
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLDDiana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Journal of Hepatology|February 9, 2024
Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclatureAmedeo Lonardo, Fernando Bril, Stephen H Caldwell, et al.
Gastroenterology|March 11, 2026
Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver DiseaseFasiha Kanwal, Fernando Bril, Vincent Wai-Sun Wong, et al.
Diabetes Care|December 23, 2020
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic ScreeningRomina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2022
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLDSrilaxmi Kalavalapalli, Eddison Godinez Leiva, Romina Lomonaco, et al.
Metabolism: Clinical and Experimental|June 21, 2020
Targeting pheochromocytoma/paraganglioma with polyamine inhibitorsSudhir Kumar Rai, Fernando Bril, Heather M Hatch, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 8, 2026
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver DiseaseZobair M Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
The Journal of Clinical Endocrinology and Metabolism|February 11, 2026
Severity of MASH Activity by Iron-Corrected MRI Predicts Insulin Resistance and Cardiometabolic Risk in Type 2 DiabetesAndrea Ortiz Rocha, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Diabetes, Obesity & Metabolism|April 29, 2026
High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology ClinicsSrilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, et al.
Obesity (Silver Spring, Md.)|September 24, 2024
Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screenAnu Sharma, Eddison Godina Leiva, Srilaxmi Kalavalapalli, et al.
Journal of Hepatology|January 17, 2025
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLDDiana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Journal of Hepatology|February 9, 2024
Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclatureAmedeo Lonardo, Fernando Bril, Stephen H Caldwell, et al.
Gastroenterology|March 11, 2026
Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver DiseaseFasiha Kanwal, Fernando Bril, Vincent Wai-Sun Wong, et al.
Diabetes Care|December 23, 2020
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic ScreeningRomina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2022
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLDSrilaxmi Kalavalapalli, Eddison Godinez Leiva, Romina Lomonaco, et al.
Metabolism: Clinical and Experimental|June 21, 2020
Targeting pheochromocytoma/paraganglioma with polyamine inhibitorsSudhir Kumar Rai, Fernando Bril, Heather M Hatch, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 8, 2026
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver DiseaseZobair M Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, et al.
Pageof 11